Trials / Completed
CompletedNCT04818346
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB054707 | INCB054707 will be administered once daily |
| DRUG | Placebo | Placebo or INCB054707 will be administered once daily |
Timeline
- Start date
- 2021-05-06
- Primary completion
- 2022-05-24
- Completion
- 2023-05-24
- First posted
- 2021-03-26
- Last updated
- 2024-04-11
- Results posted
- 2023-07-05
Locations
31 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04818346. Inclusion in this directory is not an endorsement.